Description
Udaforce (Udenafil) 100 mg
Udaforce is identified here as a product containing udenafil, a phosphodiesterase type 5 (PDE5) inhibitor used for erectile dysfunction. Udenafil has been studied as an oral treatment for adult men with erectile dysfunction, but product availability and regulatory status vary by country.
Active Ingredient and Medicine Class
Active ingredient: udenafil.
Medicine class: phosphodiesterase type 5 (PDE5) inhibitor. This class also includes medicines such as sildenafil and tadalafil.
Established Medical Uses
The main established use supported by clinical studies is the treatment of erectile dysfunction in adult men. Trials have evaluated udenafil in general erectile dysfunction, diabetes-related erectile dysfunction, hypertension-associated erectile dysfunction, and other subgroups.
How It Works
Udenafil inhibits PDE5, an enzyme that breaks down cyclic GMP in penile tissue. By preserving cyclic GMP during sexual stimulation, it helps relax smooth muscle and increases blood flow to support an erection. This is a sexual-stimulation-dependent effect rather than a direct aphrodisiac effect.
Important Safety Information
As with other PDE5 inhibitors, udenafil should not be used with nitrates because the combination can cause a dangerous drop in blood pressure. Caution is also important with other PDE5 inhibitors, riociguat, alpha-blockers, and some antihypertensive medicines, due to additive blood-pressure-lowering effects.
Important precautions seen across the PDE5 inhibitor class include cardiovascular disease, low blood pressure, recent serious heart events, and a history of vision or hearing problems. Regulatory and prescribing information for the class also warn about rare but serious events such as sudden vision loss, sudden hearing loss, prolonged erection, and hypersensitivity reactions.
Possible Side Effects
Clinical studies of udenafil most commonly reported mild to moderate adverse effects. Reported effects included headache, flushing, dizziness, nasal congestion, and digestive discomfort. Serious reactions were uncommon in the published trials, but the PDE5 inhibitor class can rarely be associated with severe cardiovascular, ocular, or auditory adverse events.
Scientific Evidence
Randomized controlled trials and a meta-analysis suggest that udenafil improves erectile function compared with placebo. One placebo-controlled trial found benefit up to 12 hours after dosing, and other trials found improvements with repeated use over several weeks. The overall published evidence supports efficacy and tolerability for erectile dysfunction, but the size and scope of the clinical evidence base are more limited than for some older PDE5 inhibitors.
Medical Information Notice
This summary is for educational use only and is based on sources available at the time of review. It does not replace the official patient leaflet, prescribing information, or assessment by a qualified healthcare professional.
Medical Sources
- European Medicines Agency (EMA): EU/3/16/1807 – orphan designation for treatment of functional single ventricle congenital heart disease
- PubMed: Moon KH et al. Efficacy of udenafil for the treatment of erectile dysfunction up to 12 hours after dosing: a randomized placebo-controlled trial. J Sex Med. 2010. PubMed article
